RxDoctor Payments Data

Erik-Brandon Buzan, PA

Physician Assistant · Scottsdale, AZNPI 1699025494

Payments from drug & device makers

$2,561in general payments, 2019–2025

Across 121 payments — averaging $21.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$484
  • Novo Nordisk$308
  • Lucid Diagnostics Inc.$263
  • Lilly USA, LLC$230
  • Eisai Inc.$201
  • AbbVie$186
  • plus $889 from 16 others

What the payments were for

  • Food & beverage$2,32991%
  • Education$2329%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,561 in reported general payments places this provider in the 80th percentile of 2,888 physician assistant providers in Arizona.

See all physician assistant providers in Arizona

Medicare billing

Part B allowed, 2024
$55,136
Medicare patients
52
Services billed
61,298

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide49$76,425
FarxigaDapagliflozin Propanediol36$33,367
ZubsolvBuprenorphine Hcl/Naloxone Hcl30$24,072
TrulicityDulaglutide12$11,388
EliquisApixaban13$7,885
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl14$3,393
Liothyronine Sodium30$2,067
Levothyroxine Sodium45$1,533
Testosterone Cypionate19$962
Albuterol Sulfate HfaAlbuterol Sulfate20$829
Hydroxyzine Hcl19$689
Modafinil12$604
Methocarbamol13$550
Testosterone13$489
Propranolol Hcl19$416

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$230$87,81461 claims
AstraZenecaFarxiga$484$33,36736 claims
Orexo US, Inc.Zubsolv$60$24,07230 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,888 physician assistant providers in Arizona.

Other physician assistant in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →